scispace - formally typeset
D

Deepu Alex

Researcher at Memorial Sloan Kettering Cancer Center

Publications -  34
Citations -  821

Deepu Alex is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 27 publications receiving 534 citations. Previous affiliations of Deepu Alex include MedStar Georgetown University Hospital & University of British Columbia.

Papers
More filters
Journal ArticleDOI

Goa1p of Candida albicans localizes to the mitochondria during stress and is required for mitochondrial function and virulence.

TL;DR: It is shown that GOA31, but not the wt or GOA32, had decreased respiration and mitochondrial membrane potential such that mutant cells are unable to drive oxidative phosphorylation, the first report in C. albicans of a respiratory defect caused by a loss of mitochondrial membranes potential.
Journal ArticleDOI

Antifungal drug discovery: the process and outcomes

TL;DR: The dogma on antifungal discovery is examined and it is suggested that a major thrust in technologies such as structural biology, homology modeling and virtual imaging is needed to drive discovery.
Journal ArticleDOI

Enzymatic Dysfunction of Mitochondrial Complex I of the Candida albicans goa1 Mutant Is Associated with Increased Reactive Oxidants and Cell Death

TL;DR: GOA1 is required for a functional CI and partially for the AOX pathway; loss of GOA1 compromises cell survival; the observation of increased ROS production associated with a defective CI and PCD is reminiscent of mitochondrial studies of patients with some types of neurodegenerative diseases where CI and/or CIII dysfunctions lead to increased ROS and apoptosis.
Journal ArticleDOI

Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.

TL;DR: A new genomically based algorithm for directing patients with osteosarcoma to clinical trial options is proposed, and at least 40% of patients have tumors harboring PDGFRA or VEGFA amplification, representing candidate subsets for clinical evaluation of additional therapeutic options.